By Sheeba M. | June 05, 2026
Federal Cannabis Reform Could Trigger 40% Upside in MSO Sector: Curaleaf and Cresco in Focus
As federal cannabis legalization discussions intensify on Capitol Hill, multistate operator valuations remain deeply discounted relative to potential upside scenarios. Curaleaf and Cresco Labs stand to benefit most from federal rescheduling, with current market caps pricing in zero probability of legislative change.
If cannabis moves from Schedule I to Schedule III (as proposed in the MORE Act variations), institutional capital would flood into MSO equities. Current trading multiples at 4-6x EBITDA would converge toward 10-12x within 12 months, translating to 40%+ stock appreciation for well-positioned operators. Cresco’s strong retail footprint in high-margin states and Curaleaf’s wholesale distribution network would be particularly advantaged.
The probability window is narrow: Congressional committee actions on cannabis bills typically trigger within Q3-Q4. Political calendars suggest late summer/early fall as the most likely catalyst window. Meanwhile, Vireo Growth has emerged as a potential acquisition target, with larger MSOs actively scouting footprint consolidation opportunities.
Risk factor: Senate opposition remains significant, with traditional enforcement advocates blocking floor votes. Current 15-20% probability of federal action by year-end is baked into valuations, but event-driven traders should monitor Capitol Hill insider activity closely—early committee passage would trigger immediate 12-18% sector rotation.
Sources
- Congress Cannabis Caucus Statement
- Marijuana Policy Project Federal Analysis
- MSO Investor Relations Guidance
Track cannabis stocks with the Weedstock Real-Time Tracker